Regeneron Pharmaceuticals, Inc (USA)

Regeneron Pharmaceuticals, Inc is a biotechnology company that invents, develops and commercializes medicines for people with serious diseases. Founded in 1988 and led by physician-scientists, the company has operated for over 35 years and employs more than 15,000 team members, among them over 1,400 holding MDs and/or PhDs. Nearly all of its approved treatments and product candidates were developed in-house.

Scientific work spans antibody discovery, fully human antibody engineering, bispecific antibody development, genetics and genomics, genetic medicine platforms, data-powered insights, drug discovery and development, and translational science. Two proprietary platforms anchor this research. VelociSuite® technologies produce optimized fully human antibodies and new classes of bispecific antibodies, while the Regeneron Genetics Center® (RGC) applies data-powered genetics research to identify new therapeutic directions.

The company maintains a global network and operates across the biotechnology, pharmaceuticals, life sciences and healthcare sectors. Its stated emphasis is on translating cutting-edge science into medicine through a discovery-driven research culture.